Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
NCT04314843 · Kite, A Gilead Company · PHASE1 · terminated · last registry update 2024-03-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Development program terminated and the decision was not due to any safety concerns.” | – | Registry record, Kite, A Gilead Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-07Results posted on the registry: GlaxoSmithKline, Otilimab (GSK3196165) + csDMARD(s) (NCT04333147)
- 2024-02-07Also stopped (terminated): GlaxoSmithKline, Otilimab (GSK3196165) + csDMARD(s) (NCT04333147)
- 2023-11-30Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib (NCT03970837)
- 2023-11-30Also stopped (terminated): GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib (NCT03970837)
- 2023-10-25Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib 5 mg (NCT03980483)
- 2023-07-17Results posted on the registry: GlaxoSmithKline, GSK3196165 (Otilimab) + Sarilumab (NCT04134728)
- 2023-06-05Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Lenzilumab + Remdesivir (NCT04583969)
- 2023-05-06Results posted on the registry: I-Mab Biopharma US Limited, TJ003234 + Placebo (NCT04341116)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision